MX2008012705A - Cocristal de derivado de c-glucosido y l-prolina. - Google Patents

Cocristal de derivado de c-glucosido y l-prolina.

Info

Publication number
MX2008012705A
MX2008012705A MX2008012705A MX2008012705A MX2008012705A MX 2008012705 A MX2008012705 A MX 2008012705A MX 2008012705 A MX2008012705 A MX 2008012705A MX 2008012705 A MX2008012705 A MX 2008012705A MX 2008012705 A MX2008012705 A MX 2008012705A
Authority
MX
Mexico
Prior art keywords
cocrystal
proline
glycoside derivative
benzothien
excelling
Prior art date
Application number
MX2008012705A
Other languages
English (en)
Inventor
Ryota Shiraki
Kenichi Onda
Daisuke Sasuga
Masakazu Imamura
Keita Nakanishi
Masamichi Yuda
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38563736&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008012705(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2008012705A publication Critical patent/MX2008012705A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

Un cocristal de (1S)-1,5-anhidro-1-[3-(1-benzotien-2-ilmetil)-4-fl uorofenil]-D-glucitol y L-prolina. Esta cocristal asegura una calidad constante, sobresaliente en estabilidad en almacenamiento, y no exhibe ninguna absorbencia de humedad, siendo un cocristal del compuesto conocido (A) siendo adecuado como un cristal de un fármaco puro para terminarse en productos farmacéuticos.
MX2008012705A 2006-04-05 2007-04-04 Cocristal de derivado de c-glucosido y l-prolina. MX2008012705A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006103711 2006-04-05
PCT/JP2007/057597 WO2007114475A1 (ja) 2006-04-05 2007-04-04 Ｃ－グリコシド誘導体とｌ－プロリンとの共結晶

Publications (1)

Publication Number Publication Date
MX2008012705A true MX2008012705A (es) 2008-10-15

Family

ID=38563736

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008012705A MX2008012705A (es) 2006-04-05 2007-04-04 Cocristal de derivado de c-glucosido y l-prolina.

Country Status (15)

Country Link
US (1) US8097592B2 (es)
EP (1) EP2009010A4 (es)
JP (1) JP5210154B2 (es)
KR (2) KR101243039B1 (es)
CN (1) CN101443328B (es)
AU (1) AU2007232763B2 (es)
BR (1) BRPI0710581A2 (es)
CA (1) CA2649022C (es)
IL (1) IL194512A0 (es)
MX (1) MX2008012705A (es)
NO (1) NO20084659L (es)
RU (1) RU2408595C2 (es)
TW (1) TWI370818B (es)
WO (1) WO2007114475A1 (es)
ZA (1) ZA200809201B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05009356A (es) * 2003-03-14 2005-12-05 Astellas Pharma Inc Derivados de c-glicosido y sales de los mismos.
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
WO2008075736A1 (ja) 2006-12-21 2008-06-26 Astellas Pharma Inc. Ｃ－グリコシド誘導体の製造方法及びその合成中間体
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
WO2009096455A1 (ja) 2008-01-31 2009-08-06 Astellas Pharma Inc. 脂肪性肝疾患の治療用医薬組成物
NZ604897A (en) 2008-08-22 2014-03-28 Theracos Sub Llc Processes for the preparation of sglt2 inhibitors
AP2728A (en) * 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
EP2491933A1 (en) * 2009-10-23 2012-08-29 Astellas Pharma Inc. Pharmaceutical composition for oral administration
JP5696156B2 (ja) 2009-11-02 2015-04-08 ファイザー・インク ジオキサ−ビシクロ［３．２．１］オクタン−２，３，４−トリオール誘導体
CA2780941C (en) 2009-11-13 2018-06-12 Bristol-Myers Squibb Company Immediate release tablet formulations
HUE040486T2 (hu) 2009-11-13 2019-03-28 Astrazeneca Ab Kétrétegû tabletta készítmények
EP2498757A1 (en) 2009-11-13 2012-09-19 Bristol-Myers Squibb Company Reduced mass metformin formulations
US20120115799A1 (en) 2010-05-11 2012-05-10 Wenhua Wang Pharmaceutical formulations
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
MX2013002146A (es) 2010-09-03 2013-04-03 Astrazeneca Uk Ltd Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua.
WO2012041898A1 (en) * 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP2670397B1 (en) 2011-02-01 2020-05-13 Bristol-Myers Squibb Company Pharmaceutical formulations including an amine compound
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2012116349A2 (en) * 2011-02-26 2012-08-30 Amplio Pharma, Llc Novel cocrystals of ezetimibe
EA028946B1 (ru) 2011-04-13 2018-01-31 Янссен Фармацевтика Нв Способ получения соединений для применения в качестве ингибиторов sglt2
KR101841087B1 (ko) * 2011-04-22 2018-03-23 아스텔라스세이야쿠 가부시키가이샤 고형 의약 조성물
US9035044B2 (en) * 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
BR112013031032A2 (pt) 2011-06-03 2016-11-29 Boehringer Ingelheim Int inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
CN103889429B (zh) 2011-10-31 2016-10-19 台湾神隆股份有限公司 Sglt2抑制剂的结晶和非结晶形式
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
ITMI20120586A1 (it) 2012-04-11 2013-10-12 Milano Politecnico Co-cristalli di 3-iodiopropinil butilcarbammato
RU2497804C1 (ru) * 2012-05-02 2013-11-10 Федеральное государственное бюджетное учреждение науки институт химии растворов им. Г.А. Крестова Российской академии наук Сокристаллическая форма 2-гидроксибензамида с 4-аминобензойной кислотой
US9145434B2 (en) * 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
EP2722327A1 (en) * 2012-10-22 2014-04-23 Quantum Genomics Crystalline phase of (3S,3S') 4,4'-disulfanediylbis (3-aminobutane 1-sulfonic acid) with L-lysine
CN103910769B (zh) * 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
EP4245765A3 (en) 2013-04-04 2024-03-20 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
CN104098572A (zh) * 2013-04-08 2014-10-15 博瑞生物医药技术(苏州)有限公司 替卡格雷共晶型
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
CN105828815B (zh) 2013-12-17 2020-03-27 勃林格殷格翰动物保健有限公司 猫科动物中代谢紊乱的治疗
CN103626710A (zh) * 2013-12-20 2014-03-12 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的共晶及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
PL3485890T3 (pl) 2014-01-23 2023-08-28 Boehringer Ingelheim Vetmedica Gmbh Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
DK3125882T3 (da) 2014-04-01 2020-06-29 Boehringer Ingelheim Vetmedica Gmbh Behandling af metabolske lidelser i hestedyr
KR101613488B1 (ko) 2014-06-18 2016-04-20 (주) 디엔디이 Mice 행사용 초대장 회답 통합관리시스템
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
EP3197429A1 (en) 2014-09-25 2017-08-02 Boehringer Ingelheim Vetmedica GmbH Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
US10220017B2 (en) 2015-08-27 2019-03-05 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising SGLT-2 inhibitors
US10428053B2 (en) 2015-09-15 2019-10-01 Laurus Labs Limited Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
CN106924206A (zh) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 一种依格列净口服固体制剂及其制备方法
US20190177258A1 (en) * 2017-12-11 2019-06-13 Artelo Biosciences, Inc. New solid forms of cannabidiol and uses thereof
US20190343853A1 (en) * 2018-04-25 2019-11-14 Theracos Sub, Llc Methods of treating hypertension
KR102097250B1 (ko) 2019-11-09 2020-04-03 유니셀랩 주식회사 신규한 이프라글리플로진의 결정형, 이의 제조방법 또는 용도
WO2021105152A1 (en) 2019-11-28 2021-06-03 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors in the drying-off of non-human mammals
JP7423800B2 (ja) 2020-02-17 2024-01-29 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコにおける心臓疾患の予防および／または治療のためのｓｇｌｔ－２阻害剤の使用
EP4138826A1 (en) 2020-04-22 2023-03-01 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
KR102660615B1 (ko) 2020-10-28 2024-04-26 동방에프티엘(주) 이프라글리플로진의 신규 공결정 및 이의 제조 방법
CN113234028B (zh) * 2021-04-29 2022-08-26 上海大学 一种5-氟尿嘧啶与肌氨酸的共晶体及其制备方法与用途
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
AU2022318037A1 (en) 2021-07-28 2024-02-22 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
KR20240041966A (ko) 2021-07-28 2024-04-01 베링거잉겔하임베트메디카게엠베하 고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
KR20240044194A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 공결정

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318272T1 (de) * 2001-04-11 2006-03-15 Bristol Myers Squibb Co Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
MXPA05009356A (es) * 2003-03-14 2005-12-05 Astellas Pharma Inc Derivados de c-glicosido y sales de los mismos.
EA015104B1 (ru) 2003-08-01 2011-06-30 Мицубиси Танабе Фарма Корпорейшн Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
NZ545133A (en) * 2003-09-04 2009-12-24 Cephalon Inc Modafinil compositions
TWI370818B (en) 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
WO2008075736A1 (ja) 2006-12-21 2008-06-26 Astellas Pharma Inc. Ｃ－グリコシド誘導体の製造方法及びその合成中間体

Also Published As

Publication number Publication date
TW200811152A (en) 2008-03-01
RU2408595C2 (ru) 2011-01-10
US8097592B2 (en) 2012-01-17
JP5210154B2 (ja) 2013-06-12
AU2007232763A1 (en) 2007-10-11
KR20120025001A (ko) 2012-03-14
KR20090015912A (ko) 2009-02-12
CN101443328A (zh) 2009-05-27
ZA200809201B (en) 2009-12-30
EP2009010A1 (en) 2008-12-31
EP2009010A4 (en) 2012-06-13
TWI370818B (en) 2012-08-21
AU2007232763B2 (en) 2011-07-28
RU2008143362A (ru) 2010-05-10
JPWO2007114475A1 (ja) 2009-08-20
CA2649022C (en) 2012-05-29
WO2007114475A1 (ja) 2007-10-11
US20090143316A1 (en) 2009-06-04
CA2649022A1 (en) 2007-10-11
BRPI0710581A2 (pt) 2011-08-16
NO20084659L (no) 2009-01-02
CN101443328B (zh) 2012-07-25
IL194512A0 (en) 2009-08-03
KR101243039B1 (ko) 2013-03-20

Similar Documents

Publication Publication Date Title
MX2008012705A (es) Cocristal de derivado de c-glucosido y l-prolina.
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
IL245688A0 (en) Crystalline solvates and complexes of (1s)-1, 5-anhydro-c-1-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids used as sglt2 inhibitors for the treatment of diabetes
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2009065919A3 (de) Organische verbindungen
NZ598972A (en) Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes
NZ591027A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2009065920A3 (de) Verbindungen
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
WO2007065808A3 (en) Neuropeptide-2 receptor-agonists
TW200637810A (en) Substituted N-aminomethylenesulfonamides, their preparation and use as medicaments
ZA201102350B (en) Pyridin-2-yl-amino-i,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
NZ595314A (en) PHARMACEUTICAL COMPOSITIONS comprising (1S)-1,5-anhydro-1-[5-(4-ethoxybenzy1)-2-methoxy-4- methylpheny1]-1-thio-D-glucitol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and metformin.
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
NZ630488A (en) Piperidine derivatives for gpr119 agonist
WO2007130825A3 (en) Fused heterocyclic compounds and their use as mglur5 modulators
WO2009065922A3 (de) Organische verbindungen
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
HK1114516A1 (en) Substituted sulfoxide compounds, methods for preparing the same and use thereof
WO2007150010A3 (en) Cyclopropyl amine derivatives as histamin h3 receptor modulators
WO2009034029A3 (de) 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten
WO2009065921A3 (de) Organischeverbindungen

Legal Events

Date Code Title Description
FG Grant or registration